Presents latest SCIB1 data at ASCO

RNS Number : 1834H

Scancell Holdings Plc

15 May 2014

 



15 May 2014

Scancell Holdings Plc

('Scancell' or the "Company")

Scancell to present latest SCIB1 data at ASCO Annual Meeting

Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that the latest data from the ongoing Phase 1/2 clinical trial of SCIB1 ImmunoBody® ('SCIB1') in patients with Stage III/IV melanoma will be presented in a poster at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 30-June 3, 2014.

SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials.  The trial is an open label, non-randomised study to determine the safety and tolerability of four dose levels of SCIB1 administered intramuscularly using an electroporation device (TDS-IM, manufactured by Ichor Medical Systems, USA).  The study will also assess immune effects and anti-tumour activity in patients with melanoma.

An earlier submitted abstract of the poster can be accessed through the ASCO website at: http://abstracts2.asco.org/.

The title, timing and location of the poster presentation is as follows:

Abstract:	3061
Title:	Phase I trial of ImmunoBody in Melanoma patients
Presenter:	Prof Poulam Patel
Session:	Developmental Therapeutics - Immunotherapy
Day/Date:	Sunday 1 June, 2014
Session Time:	8:00 am to 11:45 am
Location:	S Hall A2

For Further Information:

Dr Richard Goodfellow, Joint CEO Professor Lindy Durrant, Joint CEO	Scancell Holdings Plc Scancell Holdings Plc	+ 44 (0) 20 3727 1000
Camilla Hume/Stephen Keys	Cenkos Securities plc	+ 44 (0) 20 7397 8900
Mo Noonan/Simon Conway	FTI Consulting	+ 44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.  Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial.  Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend.  

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity.  The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

 

END

 

 

MSCDMGMKKKGGDZG